Immunotherapy Stocks
Biotechnology firms in this sector develop therapeutic platforms designed to harness the human immune system to identify and eliminate malignant cells or infectious pathogens. Revenue models center on the high-risk, high-reward lifecycle of proprietary drug discovery, ranging from early-stage gene editing and cell therapies to established commercial biologics.
As of Oct 23, 2026, Immunotherapy has 141 US-listed companies worth $2.8T combined. The median member moved +0.4% over the past week; SLS led among the 25 largest at +15.6% and RCUS trailed at -16.2%.
Companies in Immunotherapy
- JNJ – Johnson & Johnson, $645B
- ABBV – AbbVie Inc, $505B
- MRK – Merck & Company Inc, $363B
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- GILD – Gilead Sciences Inc, $193B
- BMY – Bristol-Myers Squibb Company, $129B
- GSK – GlaxoSmithKline PLC ADR, $103B
- SNY – Sanofi ADR, $99.7B
- ARGX – argenx NV ADR, $54.9B
- ROIV – Roivant Sciences Ltd, $27.1B
- BNTX – BioNTech SE, $22.9B
- SMMT – Summit Therapeutics PLC, $12.3B
- IBRX – Immunitybio Inc, $8.8B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- GRFS – Grifols SA ADR, $5.2B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- HCM – HUTCHMED DRC, $2.5B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PGEN – Precigen Inc, $2.3B
- VERA – Vera Therapeutics Inc, $2.2B
- ALVO – Alvotech, $1.9B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- VIR – Vir Biotechnology Inc, $1.8B
- PSNL – Personalis Inc, $1.7B
- NBTX – Nanobiotix, $1.7B
- IMCR – Immunocore Holdings Ltd, $1.5B
- REPL – Replimune Group Inc, $1.3B
- NKTR – Nektar Therapeutics, $1.2B
- OMER – Omeros Corporation, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- JANX – Janux Therapeutics Inc, $1.1B
- IMTX – Immatics NV, $1B
- CRVS – Corvus Pharmaceuticals Inc, $876M
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- SANA – Sana Biotechnology Inc, $835M
- CTKB – Cytek Biosciences Inc, $763M
- CADL – Candel Therapeutics Inc, $709M
- PHAR – Pharming Group NV, $690M
- AURA – Aura Biosciences Inc, $678M
- DBVT – DBV Technologies, $663M
- CTMX – CytomX Therapeutics Inc, $556M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- CBIO – Crescent Biopharma, Inc., $532M
- ALLO – Allogene Therapeutics Inc, $504M
- ACRS – Aclaris Therapeutics Inc, $483M
- AUTL – Autolus Therapeutics Ltd, $482M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- TRXB – TRex Bio, Inc. Common stock, $384M
- INDP – Indaptus Therapeutics Inc, $380M
- TTRX – Turn Therapeutics Inc. Common Stock, $337M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- AGEN – Agenus Inc, $273M
- SABS – SAB Biotherapeutics Inc, $262M
- TLSI – TriSalus Life Sciences Inc., $250M
- FATE – Fate Therapeutics Inc, $231M
- GLSI – Greenwich Lifesciences Inc, $226M
- CGEN – Compugen, $219M
- ALEC – Alector Inc, $214M
- LYEL – Lyell Immunopharma Inc, $213M
- RNAC – Cartesian Therapeutics Inc., $202M
- ELDN – Eledon Pharmaceuticals Inc, $190M
- ALXO – Alx Oncology Holdings , $173M
- ADAG – Adagene Inc, $165M
- IPHA – Innate Pharma, $160M
- NBP – NovaBridge Biosciences, $158M
- CHRS – Coherus BioSciences Inc, $156M
- CMPX – Compass Therapeutics Inc., $150M
- CLLS – Cellectis SA, $135M
- ENGN – enGene Holdings Inc. Common Stock, $119M
- CUE – Cue Biopharma, $117M
- HURA – TuHURA Biosciences Inc, $117M
- GNLX – Genelux Corporation Common Stock, $114M
- INO – Inovio Pharmaceuticals Inc, $102M
- ANIX – Anixa Biosciences Inc, $101M
- ATRA – Atara Biotherapeutics Inc, $96M
- TNXP – Tonix Pharmaceuticals Holding Corp, $93.1M
- EQ – Equillium Inc, $83.7M
- OSTX – OS Therapies Incorporated, $75.8M
- ONCY – Oncolytics Biotech Inc, $71.8M
- MAIA – MAIA Biotechnology Inc., $71.6M
- PDSB – PDS Biotechnology Corp, $66.4M
- XLO – Xilio Development Inc, $58.6M
- INMB – INmune Bio Inc, $53.6M
- INKT – Mink Therapeutics Inc, $52.2M
- ELTX – Elicio Therapeutics Inc., $50.5M
- CRBU – Caribou Biosciences Inc, $50.4M
- TVGN – Tevogen Bio Holdings Inc., $46M
- HOWL – Werewolf Therapeutics Inc, $45.2M
- CELU – Celularity Inc, $44.8M
- ACET – Adicet Bio Inc, $42.4M
- EVAX – Evaxion Biotech AS, $36.5M
- GNTA – Genenta Science SpA ADR, $34.8M
- IMMP – Immutep Ltd ADR, $32.1M
- CVM – CEL-SCI Corp, $31.5M
- BCTX – Briacell Therapeutics Corp, $30.1M
- CNTX – Context Therapeutics Inc, $28.9M
- NXTC – NextCure Inc, $24.9M
- ESLA – Estrella Immunopharma Inc., $23.3M
- BYSI – BeyondSpring Inc, $23M
- MRKR – Marker Therapeutics Inc, $17.3M
- ATYR – aTyr Pharma, Inc., $16.8M
- CTXR – Citius Pharmaceuticals Inc, $14.6M
- GTBP – GT Biopharma Inc, $14.5M
- INAB – In8bio Inc, $13.8M
- TCRX – Tscan Therapeutics Inc, $13.8M
- TPST – Tempest Therapeutics Inc, $12.8M
- INTS – Intensity Therapeutics, Inc. Common stock, $11.9M
- GDTC – CytoMed Therapeutics Limited Ordinary Shares, $11.1M
- PHIO – Phio Pharmaceuticals Corp, $10.9M
- CALC – CalciMedica, Inc. Common Stock, $8.7M
- BOLT – Bolt Biotherapeutics, $7.7M
- OSRH – OSR Holdings Inc, $7.4M
- AIM – AIM ImmunoTech Inc, $6.7M
- LNAI – Lunai Bioworks Inc., $6.3M
- IMNN – Imunon Inc, $6.1M
- XBIO – Xenetic Biosciences Inc, $5.2M
- LIMN – Liminatus Pharma, Inc. Class A Common Stock, $5M
- ENLV – Enlivex Therapeutics Ltd, $4M
- ORGS – Orgenesis Inc, $3.4M
- REVB – Revelation Biosciences Inc, $3.3M
- APVO – Aptevo Therapeutics Inc, $3.1M
- MBIO – Mustang Bio Inc, $3.1M
- GOVX – GeoVax Labs Inc, $2.9M
- HCWB – HCW Biologics Inc, $2.8M
- CLDI – Calidi Biotherapeutics Inc., $2.8M
- PPBT – Purple Biotech, $2.5M
- VBIO – Valion Bio Inc, $2.2M
- KAPA – Kairos Pharma, Ltd., $2M
- SCNI – Scinai Immunotherapeutics Ltd, $826,686
- CERO – CERo Therapeutics Holdings, Inc. Common Stock, $644,678
- CARM – Carisma Therapeutics Inc., $20,922
- SCPS – Scopus Biopharma Inc, $16,833
- VAXX – Vaxxinity Inc, $12,678
- STAB – Statera Biopharma Inc, $7,141
- ARDS – Aridis Pharmaceuticals Inc, $4,457
- EVLO – Evelo Biosciences Inc, $3,796
- NEXI – Neximmune Inc, $139